This ADC product is comprised of an anti-NCA-90 monoclonal antibody conjugated via a MC-Vc-PAB linker to SN38. The SN-38 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, SN-38 binds to DNA, causes DNA damage.
ADC Target
Name
NCA-90
Alternative Names
NCA-90
Overview
One of the nonspecific cross-reacting antigens found to be expressed on a variety of cell types. In the nomenclature of CD antigens this protein has been given the designation CD66a. NCA-90 and NCA-50 have the same sequence and the same placement of glycosylation sites despite their differences in molecular masses.
Peptide linkers, belonging to Enzymatically cleavable linkers, combine greater systemic stability with rapid enzymatic release of the drug in the target cell. The scission of peptidic bonds relies on lysosomal proteolytic enzymes, which have very low activities in blood due to endogenous inhibitors and the unfavorably high pH value of blood.
ADC payload drug
Name
SN-38 (7-ethyl-10-hydroxycamptothecin)
Description
SN38 (7-ethyl-10-hydroxy camptothecin) is an active metabolite of the cancer prodrug, irinotecan, with the ability of inhibiting Topoisomerase I, which is belong to the camptothecin family. SN-38 is formed via hydrolysis of irinotecan by carboxylesterases and metabolized via glucuronidation by UGT1A1.